Form 4: Vera Therapeutics CFO Boosts Stake with RSU, Option Grants

Vera Therapeutics' Chief Financial Officer, Sean Grant, received significant equity grants, including 25,000 restricted stock units and options for 50,000 shares, signaling increased long-term alignment.

Summary

• Sean Grant, Chief Financial Officer of Vera Therapeutics, Inc. (VERA), was granted 25,000 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) on February 4, 2026.
• These RSUs will vest in four equal annual installments, with one-fourth vesting on February 20, 2027, 2028, 2029, and 2030, contingent on continuous service.
• Grant also received stock options to purchase 50,000 shares of Class A Common Stock on February 4, 2026, with an exercise price of $42.74 per share.
• The stock options will vest monthly over 48 months, with 1/48th vesting on March 4, 2026, and subsequent monthly vesting thereafter, subject to continuous service.
• The stock options have an expiration date of February 3, 2036.
• Following these transactions, Grant directly beneficially owns 119,130 shares of Class A Common Stock (including 893 shares acquired via the 2021 Employee Stock Purchase Plan on September 12, 2025) and indirectly owns 5,000 shares via a Trust.
• Grant directly beneficially owns 50,000 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it indicates strong alignment between the Chief Financial Officer and shareholder interests through significant long-term equity grants, incentivizing sustained performance.

Positives

• The significant equity grants to the Chief Financial Officer demonstrate strong alignment between management's interests and long-term shareholder value.
• The vesting schedules for both RSUs and stock options incentivize the CFO's continued service and commitment to the company's future performance.
• The acquisition of 893 shares through the Employee Stock Purchase Plan indicates additional personal investment by the CFO in the company's stock.

Risks

• The vesting of RSUs and stock options is subject to the Reporting Person's continuous service through each vesting date, meaning the full benefit is not immediately realized and is contingent on continued employment.
• The value of the stock options is dependent on the future market price of Vera Therapeutics' Class A Common Stock exceeding the exercise price of $42.74.

Industry Context

StockSavvy.ai notes that significant equity grants to key executives like the CFO are a common practice in the biotechnology and pharmaceutical sectors. These grants are designed to align executive incentives with long-term shareholder value creation, particularly in companies like Vera Therapeutics, which are often in development stages and rely on future milestones for growth. Such grants can be viewed positively by the market as they signal management's commitment and confidence in the company's future prospects.

Comparison to Industry Standards

• Equity compensation packages, including RSUs and stock options with multi-year vesting schedules, are standard practice across the biotech industry for retaining and incentivizing executive talent.
• The vesting schedule of 1/4th annually for RSUs and 1/48th monthly for options is typical, balancing immediate reward with long-term commitment.
• The exercise price of $42.74 for the stock options reflects the market price at the time of grant, a common approach to ensure options are 'at-the-money' and provide future upside potential.

Stakeholder Impact

• Shareholders: The grants align the CFO's financial interests with long-term shareholder value, potentially leading to more focused strategic decisions aimed at increasing stock price.
• Employees: The equity grants to a key executive may signal stability and confidence in the company's future, potentially boosting morale.
• Management: The grants provide significant long-term incentives for the CFO to remain with the company and contribute to its success.

Next Steps

• The vesting of 1/48th of the stock options will commence on March 4, 2026, and continue monthly thereafter.
• The first tranche of Restricted Stock Units (one-fourth) will vest on February 20, 2027, with subsequent tranches vesting annually until 2030.

Key Dates

Recommendation

The filing details significant equity grants to a key executive, which generally signals management's confidence and long-term commitment to the company. While not a direct indicator of operational performance, increased insider alignment is a positive factor. However, a Form 4 alone does not provide sufficient information to warrant a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate, acknowledging the positive signal without overstating its immediate impact on fundamental value.

Keywords

Vera Therapeutics, VERA, Sean Grant, CFO, Form 4, SEC Filing, Restricted Stock Units, RSU, Stock Options, Equity Grant, Insider Transaction, Beneficial Ownership, Executive Compensation